New combo aims to melt fat, save muscle in obesity battle

This study tests whether combining tirzepatide (a weight-loss drug) with bimagrumab (an experimental drug) helps people with obesity lose mostly fat while keeping muscle and bone. 63 adults will receive either the combo, tirzepatide alone, or bimagrumab alone for 52 weeks. The goal is to improve body composition and insulin sensitivity without the usual muscle loss seen with weight loss.